TY - JOUR T1 - COVID-19 is an emergent disease of aging JF - medRxiv DO - 10.1101/2020.04.15.20060095 SP - 2020.04.15.20060095 AU - Didac Santesmasses AU - José Pedro Castro AU - Aleksandr A. Zenin AU - Anastasia V. Shindyapina AU - Maxim V. Gerashchenko AU - Bohan Zhang AU - Csaba Kerepesi AU - Sun Hee Yim AU - Peter O. Fedichev AU - Vadim N. Gladyshev Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/15/2020.04.15.20060095.abstract N2 - COVID-19 is an ongoing pandemic caused by the SARS-CoV-2 coronavirus that poses one of the greatest challenges to public health in recent years. SARS-CoV-2 is highly contagious and often leads to severe viral pneumonia with respiratory failure and death in the elderly and subjects with pre-existing conditions, but the reason for this age dependence is unclear. Here, we found that the case fatality rate for COVID-19 grows exponentially with age in Italy, Spain, South Korea, and China, with the doubling time approaching that of all-cause human mortality. In addition, men and those with multiple age-related diseases are characterized by increased mortality. Moreover, similar mortality patterns were found for all-cause pneumonia. We further report that the gene expression of ACE2, the SARS-CoV-2 receptor, grows in the lung with age, except for subjects on a ventilator. Together, our findings establish COVID-19 as an emergent disease of aging, and age and age-related diseases as its major risk factors. In turn, this suggests that COVID-19, and deadly respiratory diseases in general, may be targeted, in addition to therapeutic approaches that affect specific pathways, by approaches that target the aging process.Competing Interest StatementPOV is a shareholder of Gero, and POV and AAZ are Gero employeesFunding StatementSupported by NIH grants to VNGAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research has been conducted using GTEx data (dbGaP accession number phs000424.v8.p2) and the UK Biobank Resource under Application Number 21988 ER -